Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSKIRA-X: Fostamatinib long-term extension in rheumatoid arthritis
NCT01242514Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2011
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of fostamatinib in rheumatoid arthritis (RA), sponsored by AstraZeneca. Started Jan 2011; status: terminated.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01242514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01242514.